{"id":745742,"date":"2018-04-03T05:00:00","date_gmt":"2018-04-03T05:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\/"},"modified":"2025-11-07T01:27:24","modified_gmt":"2025-11-07T06:27:24","slug":"the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\/","title":{"rendered":"The European Medicines Agency Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer"},"content":{"rendered":"<p class=\"bwalignc\">       If Approved, AstraZeneca and Merck\u2019s LYNPARZA Would be the First PARP        Inhibitor to Treat Patients with Breast Cancer in Europe     <\/p>\n<p>\n      AstraZeneca and Merck (NYSE:MRK), known as MSD outside the US and<br \/>\n      Canada, today announced that the European Medicines Agency has validated<br \/>\n      for review the Marketing Authorization Application (MAA) for LYNPARZA<sup>\u00ae<br \/>\n      <\/sup>(olaparib) for use in patients with deleterious or suspected<br \/>\n      deleterious <i>BRCA<\/i>-mutated, human epidermal growth factor receptor<br \/>\n      2 (HER2)-negative metastatic breast cancer who have been previously<br \/>\n      treated with chemotherapy in the neoadjuvant, adjuvant or metastatic<br \/>\n      setting.\n    <\/p>\n<p>\n      This is the first regulatory submission for a poly ADP-ribose polymerase<br \/>\n      (PARP) inhibitor in breast cancer in Europe. If approved, the<br \/>\n      identification of a patient\u2019s <i>BRCA<\/i> status could become a critical<br \/>\n      step in the management of their disease alongside current consideration<br \/>\n      of their hormone receptor and HER2 status. The MAA is based on data from<br \/>\n      the randomized, open-label, <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1706450&amp;esheet=51782007&amp;newsitemid=20180403005179&amp;lan=en-US&amp;anchor=phase&amp;index=1&amp;md5=1f6895f36737e482bf45172664402c56\" rel=\"nofollow\">phase<\/a><br \/>\n      3 OlympiAD trial, which investigated LYNPARZA versus chemotherapy<br \/>\n      (physician\u2019s choice of capecitabine, eribulin, or vinorelbine). In the<br \/>\n      trial, LYNPARZA significantly prolonged progression-free survival<br \/>\n      compared with chemotherapy, and reduced the risk of disease progression<br \/>\n      or death by 42 percent (HR 0.58; 95% CI 0.43-0.80; P=0.0009 median 7.0<br \/>\n      vs 4.2 months).\n    <\/p>\n<p>\n      In January 2018, LYNPARZA was approved by the U.S. Food and Drug<br \/>\n      Administration for use in the treatment of <i>BRCA<\/i>-mutated<br \/>\n      HER2-negative metastatic breast cancer, becoming the first PARP<br \/>\n      inhibitor to be approved beyond ovarian cancer. LYNPARZA is available in<br \/>\n      nearly 60 countries and has been used to treat more than 20,000<br \/>\n      patients. AstraZeneca and Merck are working together to bring LYNPARZA<br \/>\n      to more patients across multiple cancers.\n    <\/p>\n<p>\n      <b>About OlympiAD<\/b>\n    <\/p>\n<p>\n      OlympiAD is a global, randomized, open-label, multi-center phase 3 trial<br \/>\n      of 302 patients, assessing the efficacy and safety of LYNPARZA<i> <\/i>tablets<br \/>\n      (300 mg twice daily) compared to physician\u2019s choice of chemotherapy. 205<br \/>\n      patients were randomized to receive LYNPARZA and<i> <\/i>97 patients were<br \/>\n      randomized to receive chemotherapy.\n    <\/p>\n<p>\n      Patients in the OlympiAD trial had germline BRCA-mutated, HER2-negative<br \/>\n      (hormone receptor-positive or triple-negative) breast cancer, and<br \/>\n      received LYNPARZA<i> <\/i>for treatment in the metastatic setting. Prior<br \/>\n      to enrollment, 71 percent of patients had received no more than two<br \/>\n      previous chemotherapy treatments for metastasized breast cancer and 28<br \/>\n      percent of patients had received prior platinum-based chemotherapy. Also<br \/>\n      enrolled, were patients with HR+ breast cancer who had received at least<br \/>\n      one endocrine therapy (adjuvant therapy or therapy for metastatic<br \/>\n      disease) and had disease progression during therapy unless they had<br \/>\n      disease for which the endocrine therapy was considered inappropriate.\n    <\/p>\n<p>\n      <b>About Metastatic Breast Cancer<\/b>\n    <\/p>\n<p>\n      Progesterone receptors (PR), estrogen receptors (ER) and HER2 receptors<br \/>\n      may be expressed on breast cancer cells. A patient\u2019s breast cancer will<br \/>\n      test either negative or positive for these three receptors. If a tumor<br \/>\n      tests positive for PR and\/or ER, it is considered HR+. If a tumor tests<br \/>\n      negative for all three receptors, it is considered triple negative.<br \/>\n      These receptors indicate which hormones or other proteins may be<br \/>\n      promoting growth of the cancer.\n    <\/p>\n<p>\n      Metastatic breast cancer (MBC) is the most advanced stage of breast<br \/>\n      cancer (Stage IV), and occurs when cancer cells have spread beyond the<br \/>\n      initial tumor site to other parts of the body outside of the breast and<br \/>\n      nearby lymph nodes.\n    <\/p>\n<p>\n      Despite the increase in treatment options during the past three decades,<br \/>\n      there is currently no cure for patients diagnosed with MBC and only 26.9<br \/>\n      percent of patients survive for five years after diagnosis. Thus, the<br \/>\n      primary aim of treatment is to slow progression of the disease for as<br \/>\n      long as possible, improving, or at least maintaining, a patient\u2019s<br \/>\n      quality of life.\n    <\/p>\n<p>\n      Breast cancer is the most common cancer in women, with an estimated 1.67<br \/>\n      million new cases diagnosed worldwide in 2012 alone &#8211; one in four of all<br \/>\n      cancer cases. Approximately 30 percent of women who are diagnosed with<br \/>\n      early breast cancer will go on to develop advanced disease.\n    <\/p>\n<p>\n      <b>About <i>BRCA<\/i> Mutations<\/b>\n    <\/p>\n<p>\n      <i>BRCA<\/i>1 and <i>BRCA<\/i>2 are human genes that produce proteins<br \/>\n      responsible for repairing damaged DNA and play an important role<br \/>\n      maintaining the genetic stability of cells. When either of these genes<br \/>\n      is mutated, or altered, such that its protein product either is not made<br \/>\n      or does not function correctly, DNA damage may not be repaired properly<br \/>\n      and cells become unstable. As a result, cells are more likely to develop<br \/>\n      additional genetic alterations that can lead to cancer.\n    <\/p>\n<p>\n      <b>About LYNPARZA (olaparib)<\/b>\n    <\/p>\n<p>\n      LYNPARZA was the first in class PARP inhibitor and the first targeted<br \/>\n      treatment to potentially exploit DNA damage response (DDR) pathway<br \/>\n      deficiencies, such as BRCA mutations, to preferentially kill cancer<br \/>\n      cells. Specifically, in vitro trials have shown that LYNPARZA-induced<br \/>\n      cytotoxicity may involve inhibition of PARP enzymatic activity and<br \/>\n      increased formation of PARP-DNA complexes, resulting in DNA damage and<br \/>\n      cancer cell death.\n    <\/p>\n<p>\n      LYNPARZA, which has the broadest clinical development program of any<br \/>\n      PARP inhibitor, is being investigated in a range of DDR-deficient tumor<br \/>\n      types.\n    <\/p>\n<p>\n      The most frequently observed adverse reactions across clinical trials in<br \/>\n      patients receiving LYNPARZA monotherapy (\u226510%) were nausea, vomiting,<br \/>\n      diarrhea, dyspepsia, fatigue, headache, dysgeusia, decreased appetite,<br \/>\n      dizziness and anemia.\n    <\/p>\n<p>\n      LYNPARZA, the first poly ADP-ribose polymerase (PARP) inhibitor<br \/>\n      approved, was initially licensed as a capsule formulation. The new<br \/>\n      tablet formulation will reduce dosing from eight capsules twice daily to<br \/>\n      two tablets twice daily.\n    <\/p>\n<p>\n      LYNPARZA is available in nearly 60 countries and has treated more than<br \/>\n      20,000 patients globally. It has the broadest clinical development<br \/>\n      program of any PARP inhibitor, and AstraZeneca and Merck are working<br \/>\n      together to bring LYNPARZA to more patients across multiple cancers. In<br \/>\n      January 2018, LYNPARZA was approved by the U.S. Food and Drug<br \/>\n      Administration for use in metastatic breast cancer, becoming the first<br \/>\n      PARP inhibitor licensed beyond ovarian cancer.\n    <\/p>\n<p>\n      <b>Indications for LYNPARZA (olaparib) in the U.S.<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with recurrent<br \/>\n      epithelial ovarian, fallopian tube, or primary peritoneal cancer, who<br \/>\n      are in complete or partial response to platinum-based chemotherapy.\n    <\/p>\n<p>\n      For the treatment of adult patients with deleterious or suspected<br \/>\n      deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who<br \/>\n      have been treated with 3 or more prior lines of chemotherapy. Select<br \/>\n      patients for therapy based on an FDA-approved companion diagnostic for<br \/>\n      LYNPARZA.\n    <\/p>\n<p>\n      In patients with deleterious or suspected deleterious gBRCAm, human<br \/>\n      epidermal growth factor receptor 2 (HER2)-negative metastatic breast<br \/>\n      cancer who have previously been treated with chemotherapy in the<br \/>\n      neoadjuvant, adjuvant or metastatic setting. Patients with hormone<br \/>\n      receptor (HR)-positive breast cancer should have been treated with a<br \/>\n      prior endocrine therapy or be considered inappropriate for endocrine<br \/>\n      treatment. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Important Safety Information for LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b><br \/>\n      (olaparib)<\/b>\n    <\/p>\n<p>\n      <b>Contraindications<\/b>\n    <\/p>\n<p>\n      There are no contraindications for LYNPARZA.\n    <\/p>\n<p>\n      <b>Warnings and Precautions<\/b>\n    <\/p>\n<p>\n      <b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML): <\/b>Occurred<br \/>\n      in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the majority<br \/>\n      of events had a fatal outcome. The duration of therapy in patients who<br \/>\n      developed secondary MDS\/AML varied from &lt;6 months to &gt;2 years. All of<br \/>\n      these patients had previous chemotherapy with platinum agents and\/or<br \/>\n      other DNA-damaging agents, including radiotherapy, and some also had a<br \/>\n      history of more than one primary malignancy or of bone marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA until patients have recovered from hematological<br \/>\n      toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete<br \/>\n      blood count for cytopenia at baseline and monthly thereafter for<br \/>\n      clinically significant changes during treatment. For prolonged<br \/>\n      hematological toxicities, interrupt LYNPARZA (olaparib) and monitor<br \/>\n      blood count weekly until recovery.\n    <\/p>\n<p>\n      If the levels have not recovered to Grade 1 or less after 4 weeks, refer<br \/>\n      the patient to a hematologist for further investigations, including bone<br \/>\n      marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA<br \/>\n      if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis: <\/b>Occurred in &lt;1% of patients exposed to LYNPARZA, and<br \/>\n      some cases were fatal. If patients present with new or worsening<br \/>\n      respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt LYNPARZA treatment and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is<br \/>\n      confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity: <\/b>Based on its mechanism of action and<br \/>\n      findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is<br \/>\n      recommended for females of reproductive potential prior to initiating<br \/>\n      treatment.\n    <\/p>\n<p>\n      <i>Females<\/i>\n    <\/p>\n<p>\n      Advise females of reproductive potential of the potential risk to a<br \/>\n      fetus and to use effective contraception during treatment and for 6<br \/>\n      months following the last dose.\n    <\/p>\n<p>\n      <i>Males<\/i>\n    <\/p>\n<p>\n      Advise male patients with female partners of reproductive potential or<br \/>\n      who are pregnant to use effective contraception during treatment and for<br \/>\n      3 months following the last dose of LYNPARZA and to not donate sperm<br \/>\n      during this time.\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014Maintenance Setting<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA in the maintenance setting for SOLO-2:<br \/>\n      nausea (76%), fatigue (including asthenia) (66%), anemia (44%), vomiting<br \/>\n      (37%), nasopharyngitis\/upper respiratory tract infection (URI)\/influenza<br \/>\n      (36%), diarrhea (33%), arthralgia\/myalgia (30%), dysgeusia (27%),<br \/>\n      headache (26%), decreased appetite (22%), and stomatitis (20%).\n    <\/p>\n<p>\n      <b>Study 19: <\/b>nausea (71%), fatigue (including asthenia) (63%),<br \/>\n      vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract<br \/>\n      infection (22%), constipation (22%), headache (21%), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the maintenance setting (SOLO-2\/Study 19)<br \/>\n      were: increase in mean corpuscular volume (89%\/82%), decrease in<br \/>\n      hemoglobin (83%\/82%), decrease in leukocytes (69%\/58%), decrease in<br \/>\n      lymphocytes (67%\/52%), decrease in absolute neutrophil count (51%\/47%),<br \/>\n      increase in serum creatinine (44%\/45%), and decrease in platelets<br \/>\n      (42%\/36%).\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014Advanced gBRCAm Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA (olaparib) for advanced gBRCAm ovarian<br \/>\n      cancer after 3 or more lines of chemotherapy (pooled from 6 studies)<br \/>\n      were: fatigue (including asthenia) (66%), nausea (64%), vomiting (43%),<br \/>\n      anemia (34%), diarrhea (31%), nasopharyngitis\/upper respiratory tract<br \/>\n      infection (URI) (26%), dyspepsia (25%), myalgia (22%), decreased<br \/>\n      appetite (22%), and arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA for advanced gBRCAm ovarian cancer (pooled<br \/>\n      from 6 studies) were: decrease in hemoglobin (90%), increase in mean<br \/>\n      corpuscular volume (57%), decrease in lymphocytes (56%), increase in<br \/>\n      serum creatinine (30%), decrease in platelets (30%), and decrease in<br \/>\n      absolute neutrophil count (25%).\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014gBRCAm, HER2-Negative Breast Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      OlympiAD were: nausea (58%), anemia (40%), fatigue (including asthenia)<br \/>\n      (37%), vomiting (30%), neutropenia (27%), respiratory tract infection<br \/>\n      (27%), leukopenia (25%), diarrhea (21%), and headache (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      OlympiAD<b> <\/b>were: decrease in hemoglobin (82%), decrease in<br \/>\n      lymphocytes (73%), decrease in leukocytes (71%), increase in mean<br \/>\n      corpuscular volume (71%), decrease in absolute neutrophil count (46%),<br \/>\n      and decrease in platelets (33%).\n    <\/p>\n<p>\n      <b>Drug Interactions<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents:<\/b> Clinical studies of LYNPARZA in combination<br \/>\n      with other myelosuppressive anticancer agents, including DNA-damaging<br \/>\n      agents, indicate a potentiation and prolongation of myelosuppressive<br \/>\n      toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors: <\/b>Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must be<br \/>\n      co-administered, reduce the dose of LYNPARZA. Advise patients to avoid<br \/>\n      grapefruit, grapefruit juice, Seville oranges, and Seville orange juice<br \/>\n      during LYNPARZA (olaparib) treatment.\n    <\/p>\n<p>\n      CYP3A Inducers:<b> <\/b>Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA. If a moderate inducer cannot be avoided,<br \/>\n      there is a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>Use In Specific Populations<\/b>\n    <\/p>\n<p>\n      <b>Lactation: <\/b>No data are available regarding the presence of<br \/>\n      olaparib in human milk, its effects on the breastfed infant or on milk<br \/>\n      production. Because of the potential for serious adverse reactions in<br \/>\n      the breastfed infant, advise a lactating woman not to breastfeed during<br \/>\n      treatment with LYNPARZA and for 1 month after receiving the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use: <\/b>The safety and efficacy of LYNPARZA have not been<br \/>\n      established in pediatric patients.\n    <\/p>\n<p>\n      <b>Hepatic Impairment: <\/b>No adjustment to the starting dose is<br \/>\n      required in patients with mild hepatic impairment (Child-Pugh<br \/>\n      classification A). There are no data in patients with moderate or severe<br \/>\n      hepatic impairment.\n    <\/p>\n<p>\n      <b>Renal Impairment: <\/b>No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment (CLcr=51-80 mL\/min). In patients<br \/>\n      with moderate renal impairment (CLcr=31-50 mL\/min), reduce the dose to<br \/>\n      200 mg twice daily. There are no data in patients with severe renal<br \/>\n      impairment or end-stage renal disease (CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>Dosing and Administration<\/b>\n    <\/p>\n<p>\n      To avoid substitution errors and overdose, do not substitute LYNPARZA<br \/>\n      tablets with LYNPARZA capsules<b> <\/b>on a milligram-to-milligram basis<br \/>\n      due to differences in the dosing and bioavailability of each<br \/>\n      formulation. Recommended tablet dose is 300 mg, taken orally twice<br \/>\n      daily, with or without food. Continue treatment until disease<br \/>\n      progression or unacceptable toxicity. For adverse reactions, consider<br \/>\n      dose interruption or dose reduction.\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      In July 2017, AstraZeneca and Merck (known as MSD outside the United<br \/>\n      States and Canada) announced a global strategic oncology collaboration<br \/>\n      to co-develop and co-commercialize LYNPARZA, the world\u2019s first PARP<br \/>\n      inhibitor and potential new medicine selumetinib, a MEK inhibitor, for<br \/>\n      multiple cancer types. The collaboration is based on increasing evidence<br \/>\n      that PARP and MEK inhibitors can be combined with PD-L1\/PD-1 inhibitors<br \/>\n      for a range of tumor types. Working together, the companies will develop<br \/>\n      LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as a monotherapy. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program evaluating our anti-PD-1 therapy across more than 30<br \/>\n      tumor types. We also continue to strengthen our immuno-oncology<br \/>\n      portfolio through strategic acquisitions and are prioritizing the<br \/>\n      development of several promising immunotherapeutic candidates with the<br \/>\n      potential to improve the treatment of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51782007&amp;newsitemid=20180403005179&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=6af3003978fec9a708ea19f96712b271\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51782007&amp;newsitemid=20180403005179&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=1687b5aaed0dbb5bb161a8704971e1ee\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51782007&amp;newsitemid=20180403005179&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=8b9b40bb379063050a2709f27cfdbfcf\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckinvents&amp;esheet=51782007&amp;newsitemid=20180403005179&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=a21af622ca1e43f7f4639f9d0e475ded\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.instagram.com%2Fmerck&amp;esheet=51782007&amp;newsitemid=20180403005179&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=dff2e46d7bc9f5711d24b8df4cffa38e\" rel=\"nofollow\">Instagram<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51782007&amp;newsitemid=20180403005179&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=60097eb087c6df071911b513ae5872ad\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51782007&amp;newsitemid=20180403005179&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=4699405779e84e489606f46835e21240\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51782007&amp;newsitemid=20180403005179&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=fd09bea6f195b4e8ee49f57b089db4c7\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see complete&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.azpicentral.com%2Flynparza_tb%2Fpi_lynparza_tb.pdf%23page%3D1&amp;esheet=51782007&amp;newsitemid=20180403005179&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=10&amp;md5=e1ca25d92c90604e9b54b17af28cc456\" rel=\"nofollow\"><br \/>\n<b>Prescribing<br \/>\n      Information<\/b><br \/>\n<\/a><br \/>\n<b> for LYNPARZA (olaparib), including Patient<br \/>\n      Information (Medication Guide)<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180403005179r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Courtney Ronaldo,        908-740-6132<br \/>Investor:<br \/>Teri Loxam, 908-740-1986<br \/>Michael        DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>If Approved, AstraZeneca and Merck\u2019s LYNPARZA Would be the First PARP Inhibitor to Treat Patients with Breast Cancer in Europe AstraZeneca and Merck (NYSE:MRK), known as MSD outside the US and Canada, today announced that the European Medicines Agency has validated for review the Marketing Authorization Application (MAA) for LYNPARZA\u00ae (olaparib) for use in patients with deleterious or suspected deleterious BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. This is the first regulatory submission for a poly ADP-ribose polymerase (PARP) inhibitor in breast cancer in Europe. If approved, the identification of a patient\u2019s BRCA status could become a critical step in the management of their disease alongside current consideration of their hormone receptor and HER2 status. The MAA is based on data from the randomized, open-label, phase 3 OlympiAD<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,289,56],"class_list":["post-745742","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The European Medicines Agency Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The European Medicines Agency Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"If Approved, AstraZeneca and Merck\u2019s LYNPARZA Would be the First PARP Inhibitor to Treat Patients with Breast Cancer in Europe AstraZeneca and Merck (NYSE:MRK), known as MSD outside the US and Canada, today announced that the European Medicines Agency has validated for review the Marketing Authorization Application (MAA) for LYNPARZA\u00ae (olaparib) for use in patients with deleterious or suspected deleterious BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. This is the first regulatory submission for a poly ADP-ribose polymerase (PARP) inhibitor in breast cancer in Europe. If approved, the identification of a patient\u2019s BRCA status could become a critical step in the management of their disease alongside current consideration of their hormone receptor and HER2 status. The MAA is based on data from the randomized, open-label, phase 3 OlympiAD\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\\\/\",\"name\":\"The European Medicines Agency Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-04-03T05:00:00+00:00\",\"dateModified\":\"2025-11-07T06:27:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The European Medicines Agency Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The European Medicines Agency Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"The European Medicines Agency Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer - Merck.com","og_description":"If Approved, AstraZeneca and Merck\u2019s LYNPARZA Would be the First PARP Inhibitor to Treat Patients with Breast Cancer in Europe AstraZeneca and Merck (NYSE:MRK), known as MSD outside the US and Canada, today announced that the European Medicines Agency has validated for review the Marketing Authorization Application (MAA) for LYNPARZA\u00ae (olaparib) for use in patients with deleterious or suspected deleterious BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. This is the first regulatory submission for a poly ADP-ribose polymerase (PARP) inhibitor in breast cancer in Europe. If approved, the identification of a patient\u2019s BRCA status could become a critical step in the management of their disease alongside current consideration of their hormone receptor and HER2 status. The MAA is based on data from the randomized, open-label, phase 3 OlympiAD","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:24+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\/","name":"The European Medicines Agency Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-04-03T05:00:00+00:00","dateModified":"2025-11-07T06:27:24+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"The European Medicines Agency Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"40793434-d8d0-4bd9-8363-06e1b536849a","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/The-European-Medicines-Agency-Accepts-Regulatory-Submission-for-LYNPARZA-olaparib-in-BRCA-Mutated-HER2-Negative-Metastatic-Breast-Can-BLJJZ.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":3,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745742\/revisions"}],"predecessor-version":[{"id":3675104,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745742\/revisions\/3675104"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745742"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}